Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 95

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 95
---
 Public Shares exercise their redemption rights with respect to a maximum of 100% of Public Shares upon consummation of the Business Combination at a redemption price of approximately $12.05 per share as of December31, 2024 (fair value as of said date). Scenario 3 includes all adjustments contained in Scenario1, presents additional adjustments to reflect the effect of the maximum redemptions and assumes that the obligations under the Backstop Agreement will be satisfied by making a cash contribution in an amount of $10,000,000 to OmnigenicsAI, considering that there will be no remaining balance in the Trust Account remaining after payment in full of the SPAC Shareholder Redemption Amount. See “ Certain Agreements Related to the Business Combination — Backstop Agreement.” 17 The combined financial statements of OmnigenicsAI have been prepared in accordance with IFRS as issued by the IASB and in its presentation currency of U.S. dollars. Financial information of its subsidiary, Heritas Argentina, was as translated from their respective functional currencies of Argentine Pesoin the case of OmnigenicsAI, based on the translation requirements provided for in IAS 21 “Foreign currencies.” Finally, the historical financial statements of APx have been prepared in accordance with GAAP in its functional and presentation currency of U.S. dollars. See “— Notes to Unaudited Pro Forma Combined Financial Information — GAAP to IFRS conversion of APx’s financial information as of December 31, 2024, for the twelve -month period ended June 30, 2024 and for the six -month period ended December 31, 2024.” The adjustments presented in the unaudited pro forma combined financial information have been identified and presented to provide relevant information necessary for an understanding of the Combined Company after giving effect to the Business Combination. SPAC and OmnigenicsAI, and its subsidiary, did not have any intercompany transactions prior to the Business Combination. Accordingly, no pro forma adjustments were required to eliminate activities between the companies. See to “ Certain APx Relationships and Related Person Transactions.” This information should be read together with OmnigenicsAI’s and SPAC’s financial statements and related notes, “ APx Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “ OmnigenicsAI Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other financial information included elsewhere in this proxy statement/prospectus. The unaudited pro forma combined financial information is presented for illustrative purposes only. Such